Therapies for multiple sclerosis, focal spasticity of the upper limb and spinal muscular atrophy (SMA) have received recommendations for PBS listing from the Pharmaceutical Benefits Advisory Committee (PBAC). At its July 2020 meeting, the PBAC recommended the following listings: Mayzent: listing of siponimod for patients with secondary progressive MS who are ambulant (with or without support). ...
3 neurology medications get PBAC recommendations, 2 in limbo
By Michael Woodhead
26 Aug 2020